Log in

Servier takes a licensing option from Iltoo Pharma Biotech

Pharmaceutical group Servier has taken a licensing option from Iltoo Pharma Biotech for the development and commercialization of low-dose interleukin-2 in the treatment of autoimmune diseases, the two companies said on Wednesday.

The licensing option agreement grants to Servier the development and commercialization rights for the ILT-101 (low-dose interleukin-2) product for the treatment of autoimmune diseases in the world, And Japan, where Iltoo Pharma retains exclusive rights, according to a statement.

The licensing option will come from an ongoing Phase II study with ILT-101 in the treatment of systemic lupus erythematosus, the results of which are expected for 2018. This international study is carried out in collaboration between the two companies.

The financial terms of the agreement stipulate that Iltoo Pharma receives an immediate payment of 8 million euros, then payments subsequent to the exercise of the option and then during stages of development and sales, for a total amount Up to 200 million.

The agreement also provides for two-digit royalties on future sales.

The development of this treatment with low-dose interleukin-2 follows the work of an academic team from APHP and Sorbonne Universities, led by Professor David Klatzmann, co-founder of Iltoo Pharma.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P